183 related articles for article (PubMed ID: 30254953)
21. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
Donnez O; Donnez J
Fertil Steril; 2020 Sep; 114(3):640-645. PubMed ID: 32507315
[TBL] [Abstract][Full Text] [Related]
22. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Matsubara S; Kawaguchi R; Akinishi M; Nagayasu M; Iwai K; Niiro E; Yamada Y; Tanase Y; Kobayashi H
Sci Rep; 2019 Nov; 9(1):17654. PubMed ID: 31776404
[TBL] [Abstract][Full Text] [Related]
23. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial.
Badawy AM; Elnashar AM; Mosbah AA
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):489-95. PubMed ID: 22229256
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review.
Lethaby A; Vollenhoven B; Sowter M
BJOG; 2002 Oct; 109(10):1097-108. PubMed ID: 12387461
[TBL] [Abstract][Full Text] [Related]
25. Role of medical therapy in the management of uterine adenomyosis.
Vannuccini S; Luisi S; Tosti C; Sorbi F; Petraglia F
Fertil Steril; 2018 Mar; 109(3):398-405. PubMed ID: 29566852
[TBL] [Abstract][Full Text] [Related]
26. Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use.
Matsushima T; Akira S; Asakura H; Takeshita T
Clin Exp Obstet Gynecol; 2017; 44(1):143-145. PubMed ID: 29714885
[TBL] [Abstract][Full Text] [Related]
27. Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist.
Manetta LA; de Paula Martins W; Rosa e Silva JC; de Sá Rosa e Silva AC; Nogueira AA; Ferriani RA
Ultrasound Med Biol; 2008 Dec; 34(12):1914-8. PubMed ID: 18597921
[TBL] [Abstract][Full Text] [Related]
28. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
29. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
Akira S; Mine K; Kuwabara Y; Takeshita T
Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
[TBL] [Abstract][Full Text] [Related]
31. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Osuga Y; Watanabe M; Hagino A
J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
[TBL] [Abstract][Full Text] [Related]
32. Biological differences between focal and diffuse adenomyosis and response to hormonal treatment.
Khan KN; Fujishita A; Koshiba A; Mori T; Kuroboshi H; Ogi H; Itoh K; Nakashima M; Kitawaki J
Reprod Biomed Online; 2019 Apr; 38(4):634-646. PubMed ID: 30850322
[TBL] [Abstract][Full Text] [Related]
33. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.
Muneyyirci-Delale O; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg E; Gillispie V; Hurtado S; Kim JH; Wang A; Wang H; Stewart EA
F S Rep; 2021 Sep; 2(3):338-346. PubMed ID: 34553161
[TBL] [Abstract][Full Text] [Related]
35. Pelvic Ultrasound in Diagnosing and Evaluating the Efficacy of Gonadotropin-Releasing Hormone Agonist Therapy in Girls With Idiopathic Central Precocious Puberty.
Yu HK; Liu X; Chen JK; Wang S; Quan XY
Front Pharmacol; 2019; 10():104. PubMed ID: 30804790
[No Abstract] [Full Text] [Related]
36. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis.
Zhang Y; Sun L; Guo Y; Cheng J; Wang Y; Fan S; Duan H
Obstet Gynecol Surv; 2014 Feb; 69(2):100-8. PubMed ID: 25112488
[TBL] [Abstract][Full Text] [Related]
37. A case of hemorrhagic shock occurred during dienogest therapy for uterine adenomyosis.
Takamura M; Koga K; Harada M; Hirota Y; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2020 Oct; ():. PubMed ID: 33090620
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy: a long-term result in a single institution.
Zhu L; Chen S; Che X; Xu P; Huang X; Zhang X
J Pain Res; 2019; 12():1917-1924. PubMed ID: 31303783
[TBL] [Abstract][Full Text] [Related]
39. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
40. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
